The Middle East and North Africa (MENA) region is undergoing a significant transformation in its pharmaceutical and healthcare industries, positioning itself as an emerging hub for manufacturing, research, and innovation. Once heavily reliant on imports, the region is now advancing rapidly toward self-reliance and strategic integration into global supply chains. Driven by strong demographic growth, […]
Read moreSearch Results for:
Perception of Value of Breakthrough Designation in Saudi Arabia
The Saudi Food and Drug Authority (SFDA) is the regulatory authority in Saudi Arabia responsible for granting national marketing authorisation for all pharmaceutical products and medical devices. For pharmaceutical products, marketing authorisation can be pursued through four distinct routes:1. Standard route: applicable to non-innovative drugs2. Priority review pathway: 40% reduction in review timelines compared to […]
Read moreThe Localization Imperative: Navigating the New Localization Requirements in Saudi Arabia
Saudi Arabia is in the midst of a national transformation under Vision 2030, a strategic roadmap for economic diversification and reducing the reliance on oil revenues. A key pillar of this strategy is the overhaul of the healthcare sector, with a primary focus on achieving national drug security. Within this framework, localization has transitioned from […]
Read moreRare Disease Funding: A Spotlight on Saudi Arabia
The Gulf Cooperation Council (GCC) region has a population of 59 million and a strong focus on developing its healthcare infrastructure and services, making it a significant region of interest for pharma and biotech companies. Economic growth, investment in technology, and a strong emphasis on local pharmaceutical development have facilitated recent growth in the sector. […]
Read moreATMPs: Critical Success Drivers for the Achievement of Premium Pricing in Saudi Arabia
The Saudi Arabian pharmaceutical market is regarded as one of the fastest growing in the world today, offering opportunities for high-cost innovative therapies, including Advanced Therapy Medicinal Products (ATMPs). ATMPs, which can be classified into gene therapy, somatic-cell therapy and tissue-engineered therapy, are regarded as one of the most ground-breaking treatment modalities for disease and […]
Read moreLook Beyond the US and Europe: Discover the Untapped Potential of the Rare Disease Market in the Middle East
As one of the most attractive and lucrative markets in the Middle East, Saudi Arabia brings a strong opportunity for pharmaceutical and biotech manufacturers to obtain high prices and uptake within the GCC region, where price referencing against Saudi Arabia is key. The opportunity in Saudi Arabia can be characterized by the major factors contributing […]
Read more